Literature DB >> 20562463

Mefloquine in the treatment of progressive multifocal leukoencephalopathy.

T E Gofton1, A Al-Khotani, B O'Farrell, L C Ang, R S McLachlan.   

Abstract

Mefloquine, an antimalarial medication with efficacy against JC virus, was used to treat progressive multifocal leukoencephalopathy. A 54-year-old woman with sarcoidosis presented with a progressive cerebellar syndrome. MRI showed lesions affecting the right cerebellum that progressed over time to the brainstem. JC virus was found in the cerebrospinal fluid (CSF), and brain biopsy confirmed the diagnosis of progressive multifocal leukoencephalopathy. Mefloquine 1000 mg/week was initiated 6 months after symptom onset. Clinical progression stopped immediately, and JC virus became undetectable in the CSF. No clinical or imaging evidence of disease progression has occurred over 20 months of follow-up. This is the first report of successful treatment of progressive multifocal leukoencephalopathy with mefloquine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562463     DOI: 10.1136/jnnp.2009.190652

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

2.  Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Authors:  N Schwab; J C Ulzheimer; R J Fox; T Schneider-Hohendorf; B C Kieseier; C M Monoranu; S M Staugaitis; W Welch; S Jilek; R A Du Pasquier; W Brück; K V Toyka; R M Ransohoff; H Wiendl
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

3.  Late relapse of progressive multifocal leucoencephalopathy postallogenic transplant in a young patient with CLL.

Authors:  Ana Sanchez-Quintana; Joaquín Breña-Atienza; Carmen Marrero-Santos; Luis Alvarez-Acosta
Journal:  BMJ Case Rep       Date:  2013-08-05

4.  A hitherto unrecognised case of progressive multifocal leukoencephalopathy.

Authors:  Huey Kuan Tan; Chun Hong Tang
Journal:  BMJ Case Rep       Date:  2015-07-23

5.  Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy.

Authors:  Jasper Fuk-Woo Chan; Maggie Kam-Man Ma; Gavin Shueng-Wai Chan; Gary Chi-Wang Chan; Garnet Kwan-Yue Choi; Kwok-Hung Chan; Vincent Chi-Chung Cheng; Kwok-Wah Chan; Bo-Ying Choy; Kwok-Yung Yuen
Journal:  Infection       Date:  2015-05-06       Impact factor: 3.553

Review 6.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Virus reactivation: a panoramic view in human infections.

Authors:  Christopher M Traylen; Hersh R Patel; Wylder Fondaw; Sheran Mahatme; John F Williams; Lia R Walker; Ossie F Dyson; Sergio Arce; Shaw M Akula
Journal:  Future Virol       Date:  2011-04       Impact factor: 1.831

Review 8.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 9.  Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.

Authors:  Stephen D Lawn; Graeme Meintjes
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

10.  Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.

Authors:  Hitoshi Yoshida; Kenji Ohshima; Jun Toda; Shinsuke Kusakabe; Hiroaki Masaie; Toshinari Yagi; Jun Ishikawa
Journal:  Int J Hematol       Date:  2013-11-22       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.